Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bayer/Onyx Report Success in Asian Trial for Nexavar

publication date: Aug 30, 2007
Liver Cancer Test Stopped Early Bayer (BAY) and Onyx (ONXX) put an early stop to a Phase III trial of Nexavar in Asia-Pacific patients because the results were positive. All patients have been put on the drug. The trial was conducted among patients with hepatocellular carcinoma, the most common form of liver cancer. The drug extended overall survival, progression-free survival and time-to-progression among the patients, though specific results will not be released until the two drug companies can present the data at a scientific conference. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital